<u>IN THE CLAIMS</u>:

Applicants, pursuant to 37 C.F.R. § 1.121, submit the following amendments to the claims:

1.   (Previously presented) An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:1, or a fragment of SEQ ID NO:1 of about 50 to 79 contiguous residues in length, wherein the polypeptide binds to the extracellular domain (ECD) of HER-2 with an affinity binding constant of at least 10^8 M^{-1}.

2.   (Previously presented) The isolated polypeptide of claim 1, wherein the isolated polypeptide is from about 69 to 79 contiguous residues in length.

3.   (Previously presented) The isolated polypeptide of claim 1, wherein the isolated polypeptide comprises SEQ ID NO:1.

4.-7.   (Cancelled).

8.   (Previously presented) An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:2, or a fragment of SEQ ID NO:2 of about 80 to 419 contiguous residues in length, wherein the C terminal 79 contiguous amino acids are present, wherein at least one N-linked glycosylation site is present, and wherein the polypeptide binds to the extracellular domain (ECD) of HER-2 with an affinity binding constant of at least 10^8 M^{-1}.

9.   (Previously presented) The isolated polypeptide of claim 8, wherein the isolated polypeptide is from about 350 to 419 contiguous residues in length and three N-linked glycosylation sites are present.

10.   (Previously presented) The isolated polypeptide of claim 8, wherein the isolated polypeptide comprises SEQ ID NO:2.

11.-17. (Cancelled).

18.   (Previously presented) A pharmaceutical composition for treating solid tumors that overexpress HER-2, comprising in a pharmaceutically acceptable carrier:

an agent selected from the group consisting of: (a) an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:1, or a fragment of SEQ ID NO:1 of about 50 to 79 contiguous residues in length, wherein the polypeptide binds to the extracellular domain (ECD) of HER-2 with

an affinity binding constant of at least 10^8 M^{-1}; (b) an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:2, or a fragment of SEQ ID NO:2 of about 80 to 419 contiguous residues in length, wherein the C terminal 79 contiguous amino acids are present, wherein at least one N-linked glycosylation site is present, and wherein the polypeptide binds to the extracellular domain (ECD) of HER-2 with an affinity binding constant of at least 10^8 M^{-1}; (c) a monoclonal antibody that binds to the extracellular domain (ECD) of HER-2; and (d) combinations thereof, with the proviso that where the composition comprises the monoclonal antibody it also comprises at least one of the agents of (a) and (b).

19. (Previously presented) The pharmaceutical composition of claim 18, wherein the agent is the isolated polypeptide comprising the amino acid sequence of SEQ ID NO:1, or a fragment of SEQ ID NO:1 of about 50 to 79 contiguous residues in length.

20. (Previously presented) The pharmaceutical composition of claim 18, wherein the agent is a combination of the isolated polypeptide comprising the amino acid sequence of SEQ ID NO:1, or a fragment of SEQ ID NO:1 of about 50 to 79 contiguous residues in length, and the monoclonal antibody that binds to the extracellular domain (ECD) of HER-2.

21.-26. (Cancelled).

27. (Previously presented) An isolated polypeptide consisting of the amino acid sequence of SEQ ID NO:1.

28. (Previously presented) An isolated polypeptide consisting of the amino acid sequence of SEQ ID NO:2.

29. (Previously presented) The pharmaceutical composition of claim 18, wherein the agent is an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:2, or a fragment of SEQ ID NO:2 of about 80 to 419 contiguous residues in length.

30. (Previously presented) The pharmaceutical composition of claim 18, wherein the agent is a combination of the isolated polypeptide comprising the amino acid sequence of SEQ ID NO:2 or a fragment of SEQ ID NO:2 of about 80 to 419 contiguous residues in length, and the monoclonal antibody that binds to the extracellular domain (ECD) of HER-2.